中危患者死亡原因:SURTAVI随机试验分析
本研究分析SURTAVI随机试验中中危主动脉瓣狭窄患者的死亡原因与时机。1年全因死亡率TAVR组6.5%、SAVR组6.7%,各时间段两组死亡率无差异。早期TAVR死亡多因技术操作问题,SAVR多因并发症;恢复期两组均以并发症为主;晚期死亡多与合并症等非手术因素相关。
要点
- 中危患者TAVR与SAVR的1年全因死亡率相似(6.5% vs 6.7%)。
- 早期死亡原因不同:TAVR多为技术失败,SAVR多为并发症。
- 恢复期死亡两组均以并发症为主,晚期死亡多与手术无关。
核心结论
- 中危患者接受TAVR或SAVR后各时间段死亡率均相似,包括1年时。
- 早期死亡原因TAVR以技术失败更常见,SAVR以并发症更常见。
- 恢复期死亡两组均以并发症为主,晚期死亡似乎与手术无关。
研究设计与样本
- SURTAVI随机试验的中危主动脉瓣狭窄患者,比较TAVR与SAVR。
- 死亡原因由独立临床事件委员会裁定,并进行事后分层分类。
- 分析三个时间段:早期(0-30天)、恢复期(31-120天)、晚期(121-365天)。
主要发现
- 1年全因死亡率TAVR组为6.5%,SAVR组为6.7%。
- 三个时间段内TAVR与SAVR的死亡率均无差异。
- 早期死亡:TAVR主要因技术、手术相关问题,SAVR因并发症。
- 恢复期死亡:两组大多数死亡由并发症导致。
- 晚期死亡:其他原因(包括合并症)占大多数。
临床怎么用
- 中危患者选择TAVR或SAVR时,应了解两者1年死亡率相似。
- TAVR术后早期需关注技术操作相关问题,SAVR术后早期需防范并发症。
- 恢复期应积极管理并发症,晚期关注合并症等非手术因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Examine the causes and timing of death in the Surgical Replacement and Transcatheter Aortic Valve Implantation intermediate-risk randomized trial for transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). METHODS: Causes of death were adjudicated by an independent clinical event committee and by post-hoc hierarchical classification. Causes of death were evaluated and characteristics and procedural parameters compared between patients who died and survivors for 3 time periods: early (0-30 days), recovery (31-120 days), and late (121-365 days). RESULTS: All-cause mortality at 1 year was 6.5% after TAVR and 6.7% after SAVR. There were no differences in mortality rates between TAVR and SAVR for any of the 3 time periods. Early mortality was primarily due to technical, procedure-related problems in TAVR and due to complications in SAVR. For TAVR and SAVR, most deaths during recovery were caused by complications. Other causes, including comorbid conditions, accounted for most late deaths. CONCLUSIONS: Mortality rates were similar for patients treated with TAVR or SAVR at any time period including at 1 year. Early cause of death was more commonly technical failure after TAVR and due to complications after SAVR. Recovery phase cause of death was dominated by complications from TAVR and SAVR. Late cause of death appeared to be independent of the procedure in both groups.
引用
- Amrane H, Deeb GM, Popma JJ, et al. Causes of death in intermediate-risk patients: The Randomized Surgical Replacement and Transcatheter Aortic Valve Implantation Trial. J Thorac Cardiovasc Surg. 2018. PMID: 30709668. doi:10.1016/j.jtcvs.2018.11.129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。